INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

For the key trials, our articles and recipes, read the Atherosclerosis & Heart Disease desk →

1,829 studies · page 53 of 77

2022 / Randomized, triple-blind, placebo-controlled, cross-over clinical trial

Celery seed extract was safe and improved blood pressure, fasting blood sugar, lipid profiles, and liver/kidney markers in hypertensive patients.

In a triple-blind, placebo-controlled crossover trial, 51 hypertensive patients received either celery seed capsules (1.34 g extract daily) or placebo for 4 weeks alongside usual medications. Celery seed extract was safe, reduced blood pressure, and decreased FBS from 108.53 to 97.96 mg/dL (p < 0.01). Significant reductions were seen in BUN (3.43 mg/dL), SCr (0.075 mg/dL), SGPT (4.08 U/L), SGOT (3.03 U/L), TC (16.37 mg/dL), TG (16.22 mg/dL), and LDL (11.84 mg/dL), along with an increase in HDL of 2.52 mg/dL (all p < 0.05 or p < 0.001). No significant changes were found in blood cells or serum electrolytes; the study was limited by a small sample size.

Shayani Rad M, Moohebati M, MohammadEbrahimi S, et al. Inflammopharmacology, 2022. PMID 35536382

2022 / Randomized, triple-blind, placebo-controlled, cross-over clinical trial

Celery seed extract significantly reduced systolic, diastolic, mean arterial, and pulse pressure in patients with hypertension.

A randomized, triple-blind, placebo-controlled crossover trial evaluated the effect of 4 celery seed extract capsules (1.34 g/day) versus placebo taken daily for 4 weeks in 52 hypertensive patients. In the celery group, systolic blood pressure decreased from 141.2 ± 5.91 to 130.0 ± 4.38 mmHg (p < .001) and diastolic blood pressure decreased from 92.2 ± 5.74 to 84.2 ± 4.87 mmHg (p < .001). Mean arterial blood pressure also changed from 108.5 ± 5.76 to 99.5 ± 4.66 mmHg (p < .001), and pulse pressure decreased from 49.0 ± 6.21 to 45.8 ± 6.01 mmHg (p < .01), whereas no significant changes occurred with placebo (p > .05). No significant side effects were reported in the celery group compared to placebo (p > .05).

Shayani Rad M, Moohebati M, Mohajeri SA Phytother Res, 2022. PMID 35624525

2022 / Uncontrolled interventional program evaluation

A 15-day whole-food plant-based program significantly reduced weight, blood pressure, cholesterol, LDL, and fasting blood sugar.

Participants enrolled in a 15-day Jumpstart program were instructed to consume an Esselstyn-compliant, whole-food plant-based diet of vegetables, fruits, whole grains, and legumes. Among 389 participants, average weight loss was 5.8 pounds (7.3 for BMI >30), systolic blood pressure dropped by 6.8 points (16.8 for baseline >140), cholesterol decreased by 26 points (44 for baseline >200), LDL dropped by 19 points (33 for baseline >100), and fasting blood sugar fell by 5.1 points (28.4 for those starting in the diabetic range). All reported comparisons achieved statistical significance (P < .005 for fasting blood sugar and P < .001 for all others).

Friedman SM, Barnett CH, Franki R, et al. Am J Lifestyle Med, 2022. PMID 35706593

2021 / Randomized, double-blind, crossover trial

Anthocyanin-rich plum juice improved postprandial vascular function and reduced C-reactive protein after a high-fat high-energy meal in overweight older adults.

Sixteen overweight older adults consumed a high-fat high-energy meal with 250 mL of either anthocyanin-rich Queen Garnet Plum juice or control apricot juice in a randomized crossover trial. Compared to control, the anthocyanin arm had higher 2-hour postprandial flow-mediated dilatation (+1.14%, P = 0.019) and higher microvascular post-occlusive reactive hyperaemia (+0.10 perfusion units per mmHg, P = 0.049). C-reactive protein was lower at 4 hours postprandially in the anthocyanin arm (1.80 mg/L) compared with control (2.30 mg/L, P = 0.026). No significant postprandial differences were found for blood pressure, lipids, oxidative metabolites, or other inflammatory markers.

do Rosario VA, Chang C, Spencer J, et al. Clin Nutr, 2021. PMID 33071012

2021 / Multicenter randomized controlled trial

Daily n-3 fatty acid supplementation did not reduce cardiovascular events in elderly patients with recent myocardial infarction.

The OMEMI trial evaluated whether adding 1.8 g of n-3 PUFA (930 mg EPA and 660 mg DHA) daily versus corn oil placebo to standard of care reduced cardiovascular events over 2 years in patients aged 70 to 82 years with recent AMI. Among 1014 analyzed patients, the primary composite endpoint occurred in 21.4% (108/505) of the n-3 PUFA group and 20.0% (102/509) of the placebo group (HR 1.08 [95% CI, 0.82-1.41]; P=0.60). New atrial fibrillation occurred in 7.2% vs 4.0% (HR 1.84 [95% CI, 0.98-3.45]; P=0.06), and major bleeding occurred in 10.7% vs 11.0% (P=0.87). The authors concluded they could not detect a reduction in clinical events with 1.8 g n-3 PUFAs daily for 2 years in this population.

Kalstad AA, Myhre PL, Laake K, et al. Circulation, 2021. PMID 33191772

2021 / Randomized open-label controlled trial

Melissa officinalis tea reduced 24-hour premature ventricular beats, triglycerides, total cholesterol, and fasting blood sugar in patients with PVCs.

A 12-week randomized trial examined the effects of Melissa officinalis (MO) tea (2 g dried leaves twice daily plus lifestyle recommendations) compared to lifestyle recommendations alone in 60 patients with PVCs. Patients receiving MO tea had significantly lower adjusted mean 24-hour premature ventricular beats (2142.39 vs. 3126.05; P = .017). They also showed significantly lower adjusted means for triglycerides (144.75 vs. 174.27 mg/dL), total cholesterol (155.35 vs. 171.99 mg/dL), and fasting blood sugar (90.85 vs. 99.84 mg/dL; P <= .042). The intervention did not significantly affect LDL-C or HDL-C levels.

Kheirkhah J, Ghorbani Z, Salari A, et al. Int J Clin Pract, 2021. PMID 34309987

2020 / Randomized, placebo-controlled, 2x2 factorial trial and meta-analyses

In the VITAL trial, vitamin D3 supplementation did not reduce total cancer incidence or major CVD events, but showed a signal for reduced cancer mortality.

The VITAL trial evaluated daily vitamin D3 (2000 IU) and marine omega-3 fatty acids (1 g) over a median of 5.3 years in 25,871 older U.S. adults. Vitamin D did not significantly reduce total invasive cancer incidence (HR = 0.96 [95% CI 0.88-1.06]), major CVD events (HR = 0.97 [0.85-1.12]), or all-cause mortality (HR = 0.99 [0.87-1.12]). However, it showed a signal for reduced total cancer mortality (HR = 0.83 [0.67-1.02]), which was significant when excluding the first year (HR = 0.79 [0.63-0.99]) or first 2 years (HR = 0.75 [0.59-0.96]) of follow-up. Updated meta-analyses including VITAL and other trials indicated a significant reduction in cancer mortality, but not cancer incidence or CVD endpoints.

Manson JE, Bassuk SS, Buring JE, et al. J Steroid Biochem Mol Biol, 2020. PMID 31733345

2020 / Randomized controlled trial

Revascularization provided no long-term quality of life or walking benefit over exercise therapy and medical therapy alone in intermittent claudication.

The IRONIC trial randomized 158 patients with mild-to-severe intermittent claudication to revascularization plus medical therapy and structured exercise, or medical therapy and structured exercise alone. At 5 years, no significant intergroup differences were observed for SF-36 scores, except for the role emotional domain which favored the nonrevascularization group (P=0.007). There were also no differences in VascuQoL scores or treadmill walking distances, while revascularization incurred nearly double the cost per patient ($13,098 vs $6,965, P=0.02).

Djerf H, Millinger J, Falkenberg M, et al. Circ Cardiovasc Interv, 2020. PMID 31937137

2020 / Randomized crossover trial

Daily non-fried potato consumption improved diet quality without altering glycemic markers in healthy adults.

Fifty healthy adults completed a randomized crossover trial comparing four weeks of daily non-fried potato side dishes against refined grains. Fasting plasma glucose did not differ between treatments (-0.05 mmol/l, 95% CI -0.14 to 0.04, P = 0.15), and no differences emerged for cardiometabolic endpoints. Potato consumption resulted in higher Healthy Eating Index-2015 scores (difference 3.5, 95% CI 0.6 to 6.4), potassium (547 mg, 95% CI 331 to 764), and dietary fiber (2.4 g, 95% CI 0.6 to 4.2).

Johnston EA, Petersen KS, Kris-Etherton PM Br J Nutr, 2020. PMID 31964428

2020 / Cluster randomized trial

A potassium-enriched salt substitute significantly increased urinary potassium and reduced systolic blood pressure in rural China.

The Salt Substitute and Stroke Study is an ongoing 5-year cluster randomized trial evaluating potassium-enriched salt substitute versus usual salt in 20,996 individuals across 600 Chinese villages. Intermediate markers assessed over 3 years showed mean differences between the intervention and control groups of -0.32 g (95% CI: -0.68 to 0.05) for 24-hour urinary sodium, +0.77 g (+0.60 to +0.93) for 24-hour urinary potassium, and -2.65 mmHg (-4.32 to -0.97) for systolic blood pressure. Diastolic blood pressure difference was +0.30 mmHg (-0.72 to +1.32). Salt substitute use was 97.5% in the intervention group versus 4.2% in controls, and the overall annual fatal and non-fatal stroke rate across the first 2 years was 3.2%.

Huang L, Tian M, Yu J, et al. Am Heart J, 2020. PMID 31986290

2020 / Randomized crossover trial

Interrupting sitting with stair climbing improved postprandial vascular measures and may help prevent vascular dysfunction after a high-fat meal.

In a randomized crossover trial, 12 healthy adults ate a high-fat meal followed by 4 hours of uninterrupted sitting or sitting interrupted every hour with 5 minutes of stair climbing. Plasma triglycerides and glucose increased after the meal and returned to baseline at the end of both trials. Brachial artery flow-mediated dilation decreased with uninterrupted sitting (9.65 ± 2.63% to 7.84 ± 2.36%) but not with interrupted sitting (9.41 ± 2.61% to 10.34 ± 3.30%, p = 0.009 for interaction). Compared with uninterrupted sitting, the interrupted trial improved popliteal blood flow and shear rate (p = 0.004 and p = 0.008 for interaction, respectively).

Cho MJ, Bunsawat K, Kim HJ, et al. Eur J Appl Physiol, 2020. PMID 32065258

2020 / Cluster randomized trial

Replacing regular salt with potassium-enriched substitute lowered blood pressure and hypertension incidence

A cluster randomized trial in 2,376 participants in Peru evaluated replacing household salt with a 75% sodium chloride and 25% potassium chloride substitute. The intervention reduced systolic blood pressure by 1.29 mm Hg (95% CI -2.17 to -0.41) and diastolic blood pressure by 0.76 mm Hg (95% CI -1.39 to -0.13). Among participants normotensive at baseline, salt substitution was linked to a 51% lower risk of developing hypertension (95% CI 29% to 66%).

Bernabe-Ortiz A, Sal Y Rosas VG, Ponce-Lucero V, et al. Nat Med, 2020. PMID 32066973

2020 / Phase II double-blind randomized placebo-controlled trial

A daily cocoa beverage improved 6-minute walk distance at 2.5 hours post-consumption in older adults with peripheral artery disease.

In a 6-month trial, 44 participants with peripheral artery disease were randomized to consume a daily cocoa beverage (15 g cocoa, 75 mg epicatechin) or a placebo. Adjusting for smoking, race, and BMI, cocoa improved 6-minute walk distance by 42.6 m (90% CI, +22.2 to +∞; P=0.005) at 2.5 hours after a final beverage, and by 18.0 m (90% CI, -1.7 to +∞; P=0.12) at 24 hours post-beverage compared to placebo. Calf muscle biopsies showed cocoa improved mitochondrial cytochrome c oxidase activity (P=0.013), increased capillary density (P=0.014), improved perfusion (P=0.098), and reduced central nuclei (P=0.033).

McDermott MM, Criqui MH, Domanchuk K, et al. Circ Res, 2020. PMID 32078436

2020 / Two-period randomized crossover trial

Consuming mixed dried fruits for 4 weeks did not improve cardiometabolic risk factors compared with an energy- and carbohydrate-matched control snack.

In a randomized crossover trial, 55 adults with elevated BMI and cardiometabolic risk consumed 3/4 cup/day of mixed dried fruits (plums, figs, dates, raisins) or an isocaloric, carbohydrate-matched control snack for 4 weeks. Lipid and lipoprotein concentrations did not differ between conditions, though dried fruit increased LDL-cholesterol from baseline (0.10 mmol/l, 95% CI 0.01, 0.20). Compared with control, dried fruit increased mean fasting glucose (0.08 mmol/l, 95% CI 0.005, 0.16; P = 0.038), while vascular outcomes, fasting insulin, and C-reactive protein did not differ. Mean weight changes did not differ between groups (P = 0.55), but tended to increase in both.

Sullivan VK, Petersen KS, Kris-Etherton PM Br J Nutr, 2020. PMID 32513313

2020 / Randomized crossover trial

Consuming plant-based alternative meat instead of animal meat lowered TMAO, LDL cholesterol, and body weight in healthy adults.

In the SWAP-MEAT crossover trial, 36 healthy adults consumed ≥2 servings/day of plant-based alternative meat versus animal meat for 8 weeks each with no washout period. Overall mean ± SEM TMAO concentrations were lower during the plant phase (2.7 ± 0.3 vs. 4.7 ± 0.9 µM, P = 0.012), though a significant order effect occurred; TMAO was significantly lower only in participants receiving plant meat second. LDL-cholesterol concentrations (109.9 ± 4.5 vs. 120.7 ± 4.5 mg/dL, P = 0.002) and body weight (78.7 ± 3.0 vs. 79.6 ± 3.0 kg, P < 0.001) were also significantly lower during the plant-based phase.

Crimarco A, Springfield S, Petlura C, et al. Am J Clin Nutr, 2020. PMID 32780794

2020 / Parallel-group, double-blind, randomized controlled trial

Vitamin K2 supplementation for one year did not improve vascular stiffness or other vascular health measures in patients with CKD stage 3b or 4.

A parallel-group, double-blind trial randomized 159 patients with CKD stage 3b or 4 to receive 400 μg oral vitamin K2 (n=80) or matching placebo (n=79) once daily for 1 year. The study found no differences between groups in carotid-femoral pulse wave velocity at 12 months, augmentation index at 12 months, blood pressure, B-type natriuretic peptide, or physical function. Furthermore, an updated meta-analysis of trials conducted by the authors showed no effect of vitamin K supplementation on vascular stiffness or vascular calcification measures.

Witham MD, Lees JS, White M, et al. J Am Soc Nephrol, 2020. PMID 32817311

2020 / Double-blind, randomized, multicenter trial

High-dose omega-3 carboxylic acid did not reduce major adverse cardiovascular events compared with corn oil in high-risk patients.

A total of 13,078 statin-treated patients at high cardiovascular risk were randomized to receive 4 g/d of an omega-3 carboxylic acid formulation (EPA/DHA) or corn oil. The trial was prematurely halted for low probability of clinical benefit. The primary composite endpoint occurred in 12.0% of omega-3 CA patients versus 12.2% of corn oil patients (hazard ratio, 0.99 [95% CI, 0.90-1.09]; P = .84). A higher rate of gastrointestinal adverse events occurred in the omega-3 group (24.7%) compared to the corn oil group (14.7%).

Nicholls SJ, Lincoff AM, Garcia M, et al. JAMA, 2020. PMID 33190147

2019 / Double-blind randomized controlled trial

One year of dietary milled flaxseed did not significantly alter cardiac arrhythmias or claudication distances compared to placebo in PAD patients.

In the double-blinded randomized controlled FLAX-PAD trial, PAD patients consumed a diet supplemented with either 30 g of milled flaxseed or placebo daily for 1 year. At baseline, cardiac arrhythmias were present in 48% of the flaxseed group and 32% of the placebo group. After 1 year, cardiac arrhythmias decreased by 2% in the flaxseed group and increased by 12% in the placebo group, which was not statistically significant (P > 0.05). Electrocardiographic variables did not change in either group, and improvements in initial and absolute claudication distances did not show a statistically significant intergroup difference.

Rodriguez-Leyva D, Rodriguez-Portelles A, Weighell W, et al. Can J Physiol Pharmacol, 2019. PMID 30308127

2019 / Multicenter, randomized, double-blind, placebo-controlled trial

Icosapent ethyl (4 g/day) significantly reduced the risk of major ischemic cardiovascular events in statin-treated patients with elevated triglycerides.

A total of 8179 statin-treated patients with elevated triglycerides were randomized to receive 2 g of icosapent ethyl twice daily (4 g total) or placebo and followed for a median of 4.9 years. The primary composite endpoint occurred in 17.2% of the icosapent ethyl group versus 22.0% of the placebo group (HR, 0.75; 95% CI, 0.68 to 0.83; P<0.001), and cardiovascular death was lower (4.3% vs. 5.2%; HR, 0.80; 95% CI, 0.66 to 0.98; P=0.03). However, hospitalizations for atrial fibrillation or flutter were higher with icosapent ethyl (3.1% vs. 2.1%, P=0.004), and serious bleeding occurred in 2.7% versus 2.1% (P=0.06).

Bhatt DL, Steg PG, Miller M, et al. N Engl J Med, 2019. PMID 30415628

2019 / Randomized, placebo-controlled trial (two-by-two factorial)

Vitamin D supplementation did not lower the incidence of invasive cancer or major cardiovascular events in older US adults.

A randomized, placebo-controlled trial tested vitamin D3 (2000 IU/day) versus placebo for the prevention of cancer and cardiovascular disease over a median follow-up of 5.3 years in 25,871 participants. Vitamin D was not associated with a lower risk of invasive cancer (HR 0.96; 95% CI, 0.88 to 1.06; P=0.47) or major cardiovascular events (HR 0.97; 95% CI, 0.85 to 1.12; P=0.69). Secondary endpoints, including death from cancer (HR 0.83; 95% CI, 0.67 to 1.02) and death from cardiovascular causes (HR 1.11; 95% CI, 0.88 to 1.40), also showed no significant differences, and no excess risks of hypercalcemia or other adverse events were identified.

Manson JE, Cook NR, Lee IM, et al. N Engl J Med, 2019. PMID 30415629

2019 / Randomized, placebo-controlled, 2x2 factorial trial

Supplementation with marine n-3 fatty acids did not reduce the incidence of major cardiovascular events or invasive cancer compared with placebo.

In the VITAL trial, 25,871 participants were randomized to 1 g per day of marine n-3 fatty acids or placebo (alongside vitamin D3 in a 2x2 factorial design) with a median follow-up of 5.3 years. Marine n-3 fatty acid supplementation did not significantly lower major cardiovascular events (HR, 0.92; 95% CI, 0.80 to 1.06; P=0.24) or invasive cancer (HR, 1.03; 95% CI, 0.93 to 1.13; P=0.56). For secondary endpoints, total myocardial infarction was lower in the n-3 group (HR, 0.72; 95% CI, 0.59 to 0.90), but stroke, cancer death, and all-cause death showed no significant differences. No excess risks of bleeding or other serious adverse events were observed.

Manson JE, Cook NR, Lee IM, et al. N Engl J Med, 2019. PMID 30415637

2019 / Controlled trial

Creatine supplementation lowered homocysteine and improved microvascular reactivity in strict vegans

In a controlled trial, 49 strict vegan participants took oral creatine monohydrate (5 g daily, n = 31) or placebo (n = 18) for three weeks. Creatine intake normalized homocysteine levels in all participants and increased blood folic acid concentrations. Supplementation also increased baseline skin capillary density and endothelium-dependent capillary recruitment, while enhancing microvascular vasodilation specifically in participants with elevated baseline homocysteine.

Van Bavel D, de Moraes R, Tibirica E Fundam Clin Pharmacol, 2019. PMID 30506745

2019 / Clinical trial

Omnivorous diets induce gut microbial pathways that convert dietary l-carnitine into proatherogenic TMAO.

Researchers evaluated isotope-labeled l-carnitine and gamma-butyrobetaine metabolism in 40 omnivores and 32 vegans or vegetarians. Following oral d3-l-carnitine, omnivores generated over 20-fold more d3-TMAO than vegans or vegetarians (P = 0.001), despite comparable fasting plasma carnitine levels. Gut bacteria transformed carnitine into gamma-butyrobetaine in both dietary groups, but conversion of gamma-butyrobetaine to TMA was induced by chronic carnitine intake and omnivorous habits.

Koeth RA, Lam-Galvez BR, Kirsop J, et al. J Clin Invest, 2019. PMID 30530985

2019 / Single-blinded randomized controlled trial

Flaxseed and psyllium improved constipation symptoms, weight, glycemia, and lipids compared to placebo in constipated patients with type 2 diabetes.

In a 12-week single-blinded trial, 77 constipated patients with type 2 diabetes received cookies containing 10 g flaxseed, 10 g psyllium, or placebo twice daily. Compared to placebo, both flaxseed and psyllium groups showed significant improvements from baseline in constipation symptoms (P = 0.002), stool consistency (P < 0.001), weight (P < 0.001), BMI (P < 0.001), fasting plasma glucose (P = 0.004), cholesterol (P = 0.010), LDL cholesterol (P = 0.031), and cholesterol/HDL cholesterol ratio (P = 0.019). Flaxseed appeared superior to psyllium for improving these markers, and no adverse effects were observed.

Soltanian N, Janghorbani M Clin Nutr ESPEN, 2019. PMID 30661699